CLR 121225

Alternative Names: (225)Ac-CLR 121225; ²²⁵Ac-CLR 121225; alpha-emitting phospholipid ether radiotherapeutic conjugate; CLR-121225

Latest Information Update: 11 Feb 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cellectar Biosciences
Class Antineoplastics; Drug conjugates; Phospholipid ethers; Radioisotopes; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Pancreatic cancer

11 Feb 2024 CLR 121225 is available for licensing as of 11 Feb 2024. https://www.cellectar.com/about/partnerships
16 Jan 2024 Cellectar Biosciences plans a phase I first-in-human study in Pancreatic cancer in early 2025 (unspecified)
16 Jan 2024 Preclinical trials in Pancreatic cancer in USA (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com